相关实验视频
Updated: Jan 12, 2026

07:37
An Adoptive Transfer Model of Rheumatoid Arthritis in Mice
Published on: June 6, 2025
984
一种新的N6-甲基氨酸抑制剂,塞拉斯特罗,通过向IGF2BP3缓解类风湿性关节炎
Qishun Geng1,2, Yi Jiao3,4, Wenya Diao3,4
1Department of Pharmacy The First Affiliated Hospital of Zhengzhou University Zhengzhou Henan China.
MedComm
|October 30, 2025
概括
塞拉斯 (CEL) 向胰岛素样生长因子-2 mRNA结合蛋白-3 (IGF2BP3),以抑制类风湿性关节炎 (RA) 的进展. 这种药物通过影响IGF2BP3/RASGRF1/mTORC1通路来减少纤维细胞样同胞细胞增殖和巨细胞炎症.
科学领域:
- 免疫学 免疫学 免疫学
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 类风湿性关节炎 (RA) 的特征是纤维细胞样同胞细胞 (FLS) 增殖和巨细胞炎症.
- 胰岛素样生长因子-2 mRNA结合蛋白-3 (IGF2BP3) 与免疫细胞和FLS功能有关,使其成为RA的潜在治疗标.
研究的目的:
- 为了识别和描述针对IGF2BP3的小分子化合物,用于潜在的RA治疗.
- 阐明塞拉斯 (CEL) 改善RA进展的机制.
主要方法:
- 分子对接和表面等离子体共振 (SPR) 用于识别CEL作为IGF2BP3抑制剂.
- 评估了CEL对RA-FLS和RAW264.7巨细胞的影响.
- 用IGF2BP3淘汰赛 (KO) 关节炎小鼠模型来验证CEL的作用机制.
主要成果:
- CEL表现出高亲和力结合IGF2BP3,导致IGF2BP3的表达减少.
- CEL抑制了RA-FLS的扩散,并降低了巨细胞的炎症激活.
- 确定IGF2BP3/RASGRF1/mTORC1轴对于CEL在RA中的治疗效果至关重要,在KO小鼠中得到证实.
结论:
- CEL有效地准IGF2BP3/RASGRF1/mTORC1轴,以减轻RA的病原性.
- CEL减少细胞增殖和炎症,为RA提供了一个有前途的治疗策略.
- 包括CEL在内的IGF2BP3抑制剂,需要在类风湿性关节炎治疗中进行临床研究.
相关概念视频
The JAK-STAT Signaling Pathway
11.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
11.9K
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
475
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
475
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
476
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
476
TGF - β Signaling Pathway
10.4K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
10.4K
T Cell Types and Functions
2.1K
When T cells with CD4 markers are activated, they give rise to two types of effector cells: helper T cells and regulatory T cells. Meanwhile, T cells with CD8 markers differentiate into effector cytotoxic T cells. The differentiation of CD4 T cells into helper T cell subsets, such as Th1, Th2, and Th17 cells, is dependent on the antigen type, antigen-presenting cell, and regulatory cytokines.
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
Th1 cells stimulate dendritic cells to express necessary co-stimulatory molecules on their surfaces for...
2.1K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
1.7K
Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
1.7K

